Pig pancreatic cell transplant improved outcomes in diabetics

05/7/2010 | Bloomberg Businessweek

No adverse events or immune system reactions were seen in patients with Type 1 diabetes who were transplanted with encapsulated pig pancreatic cells, according to a New Zealand study. After the treatment, two people were able to halt insulin shots for four weeks and 32 weeks, respectively, while others were able to lessen their daily insulin needs, the study also showed. The transplanted cells work by producing insulin in response to the high sugar levels in the patients' blood.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX